Royalty Pharma PLC
RPRX Healthcare Biotechnology
Royalty Pharma PLC’s revenue for fiscal 2025 (year ended December 2025) was $2.4 billion, up 5.06% from fiscal 2024.
- Revenue
- +13.3%
- EPS
- −51.5%
- Free cash flow
- +364.6%
- Total debt
- −4.00%
Quarter to September 2026, against a year earlier
Follow RPRX
Alert me
Royalty Pharma PLC (RPRX) Book value per share
Royalty Pharma PLC's book value per share at the end of fiscal 2025 was 22.6×, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was 22.0×. Over the past ten years it has ranged from 0.0× (fiscal 2018) to 26.4× (fiscal 2020); the current reading is higher than 63% of that period. Royalty Pharma PLC ranks 31st of 611 Biotechnology companies by book value per share.
Book value per share, annual
Embed this chart
Annual newest first
| Period | Book value per share | Change |
|---|---|---|
| FY2025 | 22.6× | (2.05%) |
| FY2024 | 23.1× | 2.43% |
| FY2023 | 22.5× | 3.59% |
| FY2022 | 21.7× | (11.97%) |
| FY2021 | 24.7× | (6.26%) |
| FY2020 | 26.4× | 61.13% |
| FY2019 | 16.4× | — |
| FY2018 | 0.0× | — |
Quarterly newest first
| Period | Book value per share | Change |
|---|---|---|
| Sep 2026 | 22.0× | (0.12%) |
| Jun 2026 | 22.0× | (3.35%) |
| Mar 2026 | 22.7× | 0.65% |
| Dec 2025 | 22.6× | 1.47% |
| 27 more quarters | Free account |
Against its own ten years
Book value per share against peers
| Company | Book value per share |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 81.8× |
| INCY Incyte Corporation compare | 27.8× |
| RPRX Royalty Pharma PLC | 22.0× |
| RVMD Revolution Medicines, Inc. compare | 11.2× |
| GMAB Genmab A/S Sponsored ADR compare | 9.7× |
| ROIV Roivant Sciences Ltd. compare | 6.8× |
| INSM Insmed, Inc. compare | 3.3× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 0.0× |
| ARGX argenex SE compare | 0.0× |
What Book value per share is
BV per Share tells an investor how much of a company’s accounting net worth stands behind each share.
(Shareholders Equity (Total) ÷ Shares (Basic, Weighted))
More on RPRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement